Ascelia Pharma AB (7ZA) Ratios
Ascelia Pharma AB Ratios
DE:7ZA's free cash flow for Q2 2026 was $-13.98M. For the 2026 fiscal year, DE:7ZA's free cash flow was increased by $0.00 and operating cash flow was $-13.98M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 4.35 | 1.35 | 2.30 | 4.29 | 10.94 |
| Quick Ratio | 4.35 | 1.35 | 2.30 | 4.29 | 10.94 |
| Cash Ratio | 4.02 | 1.21 | 1.74 | 3.99 | 10.42 |
| Solvency Ratio | -6.04 | -1.29 | -8.49 | -3.45 | -4.87 |
| Operating Cash Flow Ratio | -5.83 | -1.01 | -10.09 | -3.34 | -4.64 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -2.49 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 41.47M | $ 21.74M | $ 16.19M | $ 123.16M | $ 248.95M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.18 | 0.01 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.32 | 0.01 | 0.00 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.24 | 0.01 | 0.00 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.13 | 1.79 | 1.17 | 1.21 | 1.08 |
| Debt Service Coverage Ratio | -13.21 | -2.06 | -7731.36 | -2711.00 | -1620.73 |
| Interest Coverage Ratio | -13.46 | -9.03 | -7922.43 | -3062.65 | -1791.53 |
| Debt to Market Cap | 0.00 | 0.16 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.06 | 0.61 | 0.03 | 0.02 | 0.05 |
| Net Debt to EBITDA | 0.67 | 0.74 | 0.19 | 1.13 | 2.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 99.39% | 99.88% | 99.71% | 98.55% | 97.21% |
| EBT Per EBIT | 103.50% | 117.61% | 98.82% | 90.58% | 93.89% |
| Return on Assets (ROA) | -68.12% | -56.79% | -125.51% | -60.04% | -37.75% |
| Return on Equity (ROE) | -76.66% | -101.37% | -147.03% | -72.56% | -40.90% |
| Return on Capital Employed (ROCE) | -74.47% | -86.29% | -148.87% | -81.20% | -44.73% |
| Return on Invested Capital (ROIC) | -73.35% | -65.21% | -146.70% | -79.89% | -43.33% |
| Return on Tangible Assets | -138.97% | -95.45% | -364.32% | -81.26% | -45.55% |
| Earnings Yield | -20.88% | -50.75% | -96.18% | -26.09% | -12.80% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.43 | 0.20 | 0.69 | 0.25 | 1.42 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -839.34 | -1841.73 | -530.62 | -1489.35 | -257.21 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 839.34 | 1841.73 | 530.62 | 1489.35 | 257.21 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.64 | -1.16 | -3.76 | -3.72 | -3.54 |
| Free Cash Flow Per Share | -0.64 | -1.16 | -3.76 | -3.72 | -3.54 |
| Dividend Paid and CapEx Coverage Ratio | -1267.58 | 0.00 | 0.00 | -1927.12 | -3067.34 |
| Capital Expenditure Coverage Ratio | -1267.58 | 0.00 | 0.00 | -1927.12 | -3067.34 |
| Operating Cash Flow Coverage Ratio | -69.34 | -2.47 | -119.62 | -258.81 | -70.43 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -19.80% | -39.85% | -111.58% | -24.92% | -11.85% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.81 | -1.97 | -1.04 | -3.83 | -7.81 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.67 | 2.00 | 1.53 | 2.78 | 3.20 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.05 | -2.51 | -0.90 | -4.01 | -8.44 |
| Price-to-Operating Cash Flow Ratio | -5.06 | -2.51 | -0.90 | -4.02 | -8.44 |
| Price-to-Earnings Growth (PEG) Ratio | 0.09 | 0.04 | 0.07 | 2.93 | -4.90 |
| Enterprise Value Multiple | -4.32 | -1.59 | -0.86 | -2.68 | -5.64 |
| Enterprise Value | 316.46M | 107.82M | 92.84M | 353.93M | 723.88M |
| EV to EBITDA | -4.32 | -1.59 | -0.86 | -2.68 | -5.64 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -4.38 | -1.72 | -0.73 | -2.82 | -6.21 |
| EV to Operating Cash Flow | -4.38 | -1.72 | -0.73 | -2.83 | -6.21 |
| Tangible Book Value Per Share | 0.37 | 0.40 | 0.51 | 3.68 | 7.61 |
| Shareholders’ Equity Per Share | 0.88 | 1.46 | 2.20 | 5.37 | 9.34 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.00 | 0.00 | 0.01 | 0.03 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.67 | -1.48 | -3.24 | -3.90 | -3.82 |
| Tax Burden | 0.99 | 1.00 | 1.00 | 0.99 | 0.97 |
| Interest Burden | 1.03 | 1.18 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.97 | 0.93 | 1.16 | 0.85 | 0.84 |
Currency in SEK
